Insulin analogue: Difference between revisions

From WikiMD's Wellness Encyclopedia

Removed redirect to Insulin analog
Tag: Removed redirect
No edit summary
Line 1: Line 1:
{{Infobox drug
{{Infobox drug
| name = Insulin analog
| name = Insulin analog
| image = Insulin structure.png
| caption = Structure of human insulin, which serves as the basis for insulin analogs.
| pronounce =
| pronounce =
| tradename = [[Humalog]], [[NovoLog]], [[Lantus]], [[Levemir]], [[Tresiba]], [[Fiasp]], [[Apidra]], and others
| tradename = [[Humalog]], [[NovoLog]], [[Lantus]], [[Levemir]], [[Tresiba]], [[Fiasp]], [[Apidra]], and others

Revision as of 15:46, 13 March 2025

Insulin analogue
[[File:|frameless|220px|alt=|]]
INN
Drug class Insulin preparation
Routes of administration Subcutaneous injection, IV (for some rapid-acting analogs)
Pregnancy category Varies by analog
Bioavailability Varies
Metabolism Liver, kidney
Elimination half-life Varies (minutes to hours)
Excretion Kidney
Legal status Rx-only
CAS Number
PubChem
DrugBank
ChemSpider
KEGG


Insulin analogs are modified forms of human insulin designed to improve pharmacokinetics and pharmacodynamics, providing better glycemic control for people with diabetes mellitus. These synthetic insulins have altered amino acid sequences, affecting their absorption, distribution, metabolism, and elimination (ADME) properties.

Types of Insulin Analogs

Insulin analogs are classified into rapid-acting, long-acting, and ultra-long-acting formulations based on their onset and duration of action.

Rapid-acting Insulin Analogs

Used to control postprandial blood glucose spikes.

Rapid-Acting Insulin Analogs
Name Brand Names Onset of Action Peak Effect Duration
Insulin lispro Humalog, Admelog ~15 min 1–2 hours 3–5 hours
Insulin aspart NovoLog, Fiasp ~10–20 min 1–3 hours 3–5 hours
Insulin glulisine Apidra ~15 min 1–2 hours 3–5 hours

Long-acting and Ultra-long-acting Insulin Analogs

Used to maintain basal insulin levels throughout the day.

Long-Acting and Ultra-Long-Acting Insulin Analogs
Name Brand Names Onset of Action Peak Effect Duration
Insulin glargine Lantus, Toujeo, Basaglar ~1–2 hours No significant peak 18–24 hours
Insulin detemir Levemir ~1–2 hours Minimal peak 12–24 hours
Insulin degludec Tresiba ~1 hour No significant peak >42 hours

Mechanism of Action

Insulin analogs work by: 1. Binding to the insulin receptor (IR) on target cells (liver, muscle, adipose). 2. Stimulating glucose uptake via GLUT4 transporters. 3. Inhibiting hepatic glucose production and promoting glycogen synthesis. 4. Suppressing lipolysis and proteolysis.

The modifications in insulin analogs affect their absorption rate and receptor affinity, providing a more physiological insulin profile.

Advantages of Insulin Analogs

Compared to human insulin, insulin analogs offer:

  • Faster onset (e.g., rapid-acting analogs for meal coverage).
  • Prolonged basal action (e.g., ultra-long-acting insulin reduces nocturnal hypoglycemia).
  • Lower risk of hypoglycemia (especially long-acting formulations).
  • More predictable absorption with less variability.

Clinical Indications

Insulin analogs are used for:

  • Type 1 diabetes mellitus (T1DM) – Requires both basal and bolus insulin.
  • Type 2 diabetes mellitus (T2DM) – Used when oral hypoglycemic agents fail.
  • Gestational diabetes mellitus (GDM) – Preferred over human insulin for better glycemic control.
  • Diabetic ketoacidosis (DKA)IV insulin analogs used in critical care settings.

Comparison with Human Insulin

Comparison of Insulin Analogs vs. Human Insulin
Feature Human Insulin Insulin Analogs
Onset of action Slower (30–60 min) Faster (10–15 min for rapid-acting)
Duration Shorter or longer (varies) More predictable
Risk of hypoglycemia Higher Lower (especially nocturnal hypoglycemia)
Absorption variability Higher Lower

Potential Side Effects

Common side effects include:

  • Hypoglycemia (risk varies by type of insulin).
  • Weight gain (due to anabolic effects of insulin).
  • Injection site reactions (e.g., lipodystrophy).
  • Allergic reactions (rare but possible).
  • Hypokalemia (can lead to cardiac arrhythmias).

Special Considerations

  • Renal impairment – Adjust dosing for patients with chronic kidney disease (CKD).
  • Liver dysfunction – Insulin metabolism is reduced in hepatic impairment.
  • Pregnancy and lactation – Some analogs (e.g., insulin detemir) are FDA-approved for pregnancy.

Future Developments

Research is ongoing for:

  • Oral insulin formulations (to improve compliance).
  • Smart insulin pumps (automated insulin delivery systems).
  • Ultra-rapid insulins (faster onset for meal-time control).

See Also